



Aldeyra Therapeutics to Host R&D Day on Tuesday, March 29, 2022

March 22, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 22, 2022-- [Aldeyra Therapeutics, Inc.](#) (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that it will host a Research & Development Day from 10:00 a.m. to 12:30 p.m. ET on Tuesday, March 29, 2022 in New York City.

Aldeyra will announce top-line data from the Phase 2 proof-of-concept clinical trials of ADX-629, a first-in-class orally administered RASP modulator, in three types of inflammatory disease, and will discuss new indications selected for clinical development.

The event will feature presentations from members of the Aldeyra senior leadership team and Geoffrey M. Thiele, Ph.D., Umbach Professor of Rheumatology in the Department of Internal Medicine, Division of Rheumatology and Immunology, at the University of Nebraska Medical Center.

A live audio webcast and slide presentation will be accessible from the "Investors & Media" section of the Aldeyra website at <https://ir.aldeyra.com/>. A replay of the webcast will be available for 90 days following the event.

About Aldeyra Therapeutics

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit <https://www.aldeyra.com/> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220321005884/en/): <https://www.businesswire.com/news/home/20220321005884/en/>

Corporate:

Joshua Reed
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
jreed@aldeyra.com

Investor & Media:

Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 857-383-2409
ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.